Immupharma PLC Share Subscription into Incanthera plc (3634A)
September 29 2020 - 2:00AM
UK Regulatory
TIDMIMM TIDMINC
RNS Number : 3634A
Immupharma PLC
29 September 2020
29 September 2020
ImmuPharma plc
("ImmuPharma" or the "Company")
Share Subscription into Incanthera plc
("Incanthera")
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, announces that
further to a subscription agreement entered into at the time of
Incanthera's IPO onto AQSE Growth Market* in February 2020,
ImmuPharma has now executed its subscription agreement to subscribe
GBP250,000 for 2,631,579 ordinary shares of 2p each at a
subscription price equal to Incanthera's IPO price of 9.5p
each.
Following this subscription, ImmuPharma will hold 9,904,319
shares in Incanthera, representing a 15.35% position in the
enlarged share capital of Incanthera.
ImmuPharma notes two recent positive announcements from
Incanthera regarding studies of its lead product Sol, a potentially
innovative topical product for the treatment of solar keratosis and
the prevention of skin cancers. These announcements can be viewed
on Incanthera's website:
http://www.incanthera.com/news-media/news/2020/september/successful-results-of-permeation-study/
http://www.incanthera.com/news-media/news/2020/september/successful-results-of-sensitisation-study/
Commenting on the announcement, Dimitri Dimitriou, ImmuPharma's
Chief Executive Officer said:
"ImmuPharma is a strong supporter of Incanthera, sharing common
goals of progressing both of our therapeutic pipelines to benefit
the long term health of patients, globally.
We are extremely pleased to note Incanthera's two recent
announcements, evidencing great progress towards its immediate goal
of taking its lead product Sol to market."
*Formerly known as NEX Exchange Growth Market
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR").
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, anti-infectives,
metabolic diseases and cancer.
The lead program, Lupuzor(TM), is a first-in class autophagy
immunomodulator which is in Phase III for the treatment of systemic
lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease
which if left untreated can be fatal. Preclinical analysis suggests
therapeutic activity for many other autoimmune diseases that share
the same autophagy mechanism of action. ImmuPharma and Avion
Pharmaceuticals signed on 28 November 2019, an exclusive licence
and development agreement and trademark agreement for Lupuzor(TM)
to fund a new international Phase III trial for Lupuzor(TM) and
commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk .
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
About Incanthera plc
Incanthera (AQSE: INC), is a specialist oncology company focused
on transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers.
For more information please visit: www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKKFBQFBKDBCB
(END) Dow Jones Newswires
September 29, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024